Pretreatment anemia and survival in nasopharyngeal carcinoma

• DOI: 10.1007/s13277-015-4042-6
• Publication Date: 2015-09-10T13:47:59Z
• Authors: Lu-Ning Zhang; Jie Tang; Xiao-Wen Lan; Pu-Yun OuYang; Fang-Yun Xie
• Keywords: Adult; Male; Nasopharyngeal Carcinoma; Carcinoma; Anemia; Nasopharyngeal Neoplasms; Chemoradiotherapy; Kaplan-Meier Estimate; Middle Aged; Prognosis; Disease-Free Survival; 3. Good health; Young Adult; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Humans; Female; Aged; Proportional Hazards Models; Retrospective Studies

Due to the low incidence of pretreatment anemia in nasopharyngeal carcinoma (NPC), true prognostic impact may be underestimated before. We retrospectively analyzed association with disease-specific survival (DSS), distant-metastasis-free (DMFS), and locoregional-relapse-free (LRFS) by Cox regression a cohort 5830 patients, stratifying midtreatment anemia, smoking, body mass index (BMI), etc. Pretreatment was significantly associated adverse DSS (hazard ratio (HR) = 2.15, 95 % confidence interval (CI) 1.62-2.85, P < 0.001) DMFS (HR 1.53, CI 1.08-2.17, 0.018), comparing patients normal hemoglobin, after adjusting for covariates. Moreover, remained unchanged regardless smoking status clinical stage, whereas it limited subgroups above 45 years, male sex, BMI <25 kg/m(2). With restriction anemic still strongly correlated inferior DMFS. This study, largest reported cohort, is first show on NPC.